News|Articles|May 15, 2026

FDA Approves Tecentriq for Bladder Cancer With Detected DNA After Surgery

Fact checked by: Alex Biese

Listen

0:00 / 0:00

Key Takeaways

FDA approved adjuvant atezolizumab for post-cystectomy MIBC with ctDNA MRD positivity, alongside Signatera CDx as the required companion diagnostic for eligibility determination.
IMvigor011 randomized 250 MRD-positive patients to atezolizumab 1680 mg q4w versus placebo for up to 12 months, starting ≥6 weeks postoperatively during 12-month surveillance.
Efficacy favored atezolizumab with median DFS 9.9 vs 4.8 months and median OS 32.8 vs 21.1 months, both statistically significant.
Toxicity precautions mirror PD-(L)1 blockade, including immune-mediated organ toxicities, infusion-related reactions, embryo-fetal harm, and considerations around allogeneic HSCT.
Dosing flexibility includes IV schedules (840 q2w, 1200 q3w, 1680 q4w) and SC atezolizumab/hyaluronidase 1875 mg/30,000 units q3w, for up to one year.

The FDA approved Tecentriq for patients with muscle-invasive bladder cancer who still have detectable signs of tumor DNA in their blood after surgery.

Patients with muscle-invasive bladder cancer (MIBC) now have a new treatment option. The FDA recently approved Tecentriq (atezolizumab) for adults whose cancer was removed by surgery but who still show signs of circulating tumor DNA (ctDNA), or tiny traces of cancer found in the blood. This targeted approach uses a specialized test to identify who might benefit most from this additional therapy.

In a simultaneous move, the FDA approved the Signatera CDx (Natera, Inc.) as the companion diagnostic device required to identify eligible patients. This regulatory milestone marks a shift toward precision monitoring in the post-surgical setting for bladder cancer.

Clinical trial data: IMvigor011

The approval is supported by results from the IMvigor011 trial, a multi-center, randomized, double-blind, placebo-controlled study. The trial enrolled 250 patients with MIBC who underwent radical cystectomy with lymph node dissection. To be eligible, patients had to have molecular residual disease (MRD) detected via serial ctDNA blood evaluations during the 12 months following surgery, beginning at least six weeks post-operation.

Participants were randomized to receive either 1680 mg of Tecentriq intravenously or a placebo every four weeks. Treatment duration lasted up to one year (12 cycles) or until disease recurrence or unacceptable toxicity occurred.

The primary efficacy endpoint was investigator-assessed disease-free survival (DFS), with overall survival (OS) serving as an additional outcome measure. Data revealed a statistically significant improvement in DFS for the Tecentriq arm, with a median DFS of 9.9 months for Tecentriq versus 4.8 months for placebo. Improvements in OS were also statistically significant, with a median OS of 32.8 months for Tecentriq versus 21.1 months for placebo.

Safety profile and precautions

The prescribing information for both the intravenous and subcutaneous formulations includes boxed warnings and precautions common to the checkpoint inhibitor class. Care teams should monitor patients for immune-mediated adverse reactions, which can affect any organ system. Other documented risks include infusion-related reactions, embryo-fetal toxicity and complications associated with allogeneic hematopoietic stem cell transplantation.

Considerations formm administration

The FDA approval covers two distinct administration routes, offering flexibility for both clinical workflow and patient preference:

Intravenous Tecentriq: Dosing schedules include 840 mg every two weeks, 1200 mg every three weeks or 1680 mg every four weeks.
Subcutaneous Tecentriq and Hyaluronidase-tqjs: This formulation includes 1875 mg of Tecentriq and 30,000 units of hyaluronidase administered every three weeks.

For both formulations, treatment is recommended for up to one year unless recurrence or toxicity intervenes.

The role of companion diagnostics

A critical component of this new treatment paradigm is the integration of serial testing. Patients who initially test negative via the Signatera CDx should not receive the immunotherapy immediately; instead, they are advised to continue serial testing. If a patient tests positive for ctDNA MRD within the 12-month post-surgical window, they then become eligible for adjuvant Tecentriq.

This application was granted Priority Review, a designation reserved for drugs that offer significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions. The review was further facilitated by the use of the Assessment Aid, a voluntary submission from the manufacturer to streamline the FDA’s evaluation process.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.